COMPASS: Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia

COMPASS: Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia

Rationale : Volanesorsen is an antisense oligonucleotide that targets hepatic
apolipoprotein C-III synthesis and reduces plasma triglyceride concentration. To explore
the safety and efficacy of volanesorsen in patients with chylomicronaemia syndrome.

Infographic

Reference

Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, Hughes SG, Gaudet D, Hegele RA, O’Dea LSL, Stroes ESG, Tsimikas S, Witztum JL; COMPASS study group. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 May;9(5):264-275.

>